Published in Genet Med on October 01, 2011
The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med (2014) 1.68
Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment. Clin Med Insights Oncol (2014) 0.84
Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol (2013) 0.83
Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study. BMC Cancer (2012) 0.81
Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits (2014) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med (2005) 14.47
Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA (2008) 10.92
MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med (2007) 10.28
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med (2008) 5.13
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med (1997) 4.66
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA (2006) 2.53
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol (2010) 2.12
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol (2007) 2.09
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer (2007) 2.03
Cancer's next frontier: addressing high and increasing costs. JAMA (2010) 1.93
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol (2005) 1.83
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol (2002) 1.68
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med (2006) 1.57
Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol (1999) 1.57
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ (2007) 1.53
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist (2010) 1.42
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health (2010) 1.40
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer (2007) 1.40
Costing and perspective in published cost-effectiveness analysis. Med Care (2009) 1.36
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer (2006) 1.16
Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat (2008) 1.09
Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat (2010) 1.07
Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer (2009) 1.03
Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res (2009) 1.01
Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J (2004) 0.99
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol (2007) 0.99
Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics (2007) 0.98
Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol (2009) 0.96
Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health (2008) 0.96
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol (2007) 0.95
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol (2007) 0.93
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health (2010) 0.93
Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy (2008) 0.92
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest (2009) 0.86
The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care (1999) 0.86
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health (2011) 0.85
The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat (2007) 0.83
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med (2005) 3.55
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Optical biopsy of sessile serrated adenomas: do these lesions resemble hyperplastic polyps under narrow-band imaging? Gastrointest Endosc (2013) 2.80
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer (2009) 2.63
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc (2011) 2.51
Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care (2002) 2.34
Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care (2004) 2.25
Trends in colonoscopy for colorectal cancer screening. Med Care (2007) 1.89
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Colonoscopic treatment of acute diverticular hemorrhage using endoclips. Dig Dis Sci (2007) 1.69
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2014) 1.65
Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res (2006) 1.64
The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health (2003) 1.53
Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol (2013) 1.52
Sedation for gastrointestinal endoscopy: new practices, new economics. Am J Gastroenterol (2005) 1.51
Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology (2004) 1.49
Behavioral health services for women who have breast cancer. J Clin Oncol (2008) 1.45
Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst (2013) 1.45
Rates and predictors of colorectal cancer screening. Prev Chronic Dis (2006) 1.31
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care (2008) 1.30
The effect of area HMO market share on cancer screening. Health Serv Res (2004) 1.29
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract (2011) 1.25
Discordant indigenous and provider frames explain challenges in improving access to arthritis care: a qualitative study using constructivist grounded theory. Int J Equity Health (2014) 1.23
How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood) (2006) 1.21
Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol (2013) 1.16
Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol (2012) 1.16
How does cost matter in health-care discrete-choice experiments? Health Econ (2011) 1.15
Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst (2013) 1.14
An experiment on simplifying conjoint analysis designs for measuring preferences. Health Econ (2003) 1.14
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
The Alberta Hip and Knee Replacement Project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Technol Assess Health Care (2009) 1.13
The yield of lower endoscopy in patients with constipation: survey of a university hospital, a public county hospital, and a Veterans Administration medical center. Gastrointest Endosc (2002) 1.13
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13
Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract (2011) 1.10
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med (2011) 1.07
Education does pay off: pneumococcal vaccine screening and administration in hospitalized adult patients with pneumonia. J La State Med Soc (2004) 1.06
Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006. Contraception (2010) 1.06
Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res (2004) 1.03
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol (2009) 0.99
Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care (2004) 0.97
Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst (2012) 0.95
Disparities in cancer screening in individuals with a family history of breast or colorectal cancer. Cancer (2011) 0.95
Breast biopsy patterns and outcomes in Surveillance, Epidemiology, and End Results-Medicare data. Cancer (2009) 0.95
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Clinical and economic burden of emergency department visits due to gastrointestinal diseases in the United States. Am J Gastroenterol (2013) 0.94
Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood) (2006) 0.94
Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis (2007) 0.92
Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities. Cancer (2012) 0.92
Proximal and distal colorectal cancer resection rates in the United States since widespread screening by colonoscopy. Gastroenterology (2012) 0.91
Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues (2006) 0.91
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol (2009) 0.91
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol (2005) 0.91
Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care (2003) 0.90
Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer (2011) 0.90
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care (2011) 0.90
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf (2007) 0.88
Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control (2004) 0.88
Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. JAMA (2012) 0.88
Cost-utility of metal-on-metal hip resurfacing compared to conventional total hip replacement in young active patients with osteoarthritis. Value Health (2013) 0.88
Medicare formulary coverage for top-selling biologics. Nat Biotechnol (2009) 0.87
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med (2009) 0.87
Melanosis coli. Clin Gastroenterol Hepatol (2008) 0.87
Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer (2012) 0.87
Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract (2012) 0.87
Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Qual Life Res (2015) 0.86
Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol (2008) 0.86
Colorectal cancer screening differential costs for younger versus older Americans. Am J Prev Med (2006) 0.86
Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol (2009) 0.86
Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer (2012) 0.86
Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives. Fam Cancer (2014) 0.85
Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer (2012) 0.85
Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med (2010) 0.85
Functional outcomes for 2 years comparing hip resurfacing and total hip arthroplasty. J Arthroplasty (2012) 0.85
The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Health Policy (2007) 0.83
Angiotensin receptor blockers on the formularies of Medicare drug plans. J Gen Intern Med (2007) 0.83
Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Contraception (2006) 0.83
Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care (2011) 0.83
An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. BMC Med Res Methodol (2012) 0.82
Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract (2011) 0.81
Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care (2011) 0.81
Preferences for genetic testing to identify hereditary colorectal cancer: perspectives of high-risk patients, community members, and clinicians. J Cancer Educ (2012) 0.81
Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Value Health (2007) 0.81
Do economic evaluations of targeted therapy provide support for decision makers? Am J Manag Care (2011) 0.81
Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol (2010) 0.81
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat (2011) 0.80